“If this blog helped you out, don’t keep it to yourself—share the link on your socials!” 👍 “Like what you read? Spread the love and share this blog on your social media.” 👍 “Found this useful? Hit share and let your friends know too!” 👍 “If you enjoyed this post, please share the URL with your friends online.” 👍 “Sharing is caring—drop this link on your social media if it helped you.”

Sunday, August 31, 2025

Dynavax Technologies Corporation


Dynavax Technologies Corporation products


C

  • CpG 1018® (vaccine adjuvant)

    • Utilized in their marketed vaccine HEPLISAV-B® and incorporated into several COVID-19 vaccines globally.

H

  • HEPLISAV-B® — Hepatitis B vaccine (recombinant), adjuvanted

    • Indication: Prevention of hepatitis B infection in adults. Administered in just two doses in one month for series completion.

P

  • Plague Vaccine Program

    • Investigational candidate: rF1V vaccine for plague prevention, adjuvanted with CpG 1018 under development through a collaboration with the U.S. Department of Defense.

S

  • Shingles Vaccine Program (Z-1018)

    • Investigational herpes zoster (shingles) vaccine, adjuvanted with CpG 1018; currently in Phase 1/2 trials, showing strong immune response and improved safety compared to existing vaccines.



on

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)